Physiologically-based toxicokinetic modeling of zearalenone and its metabolites: Application to the Jersey girl study

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Mukherjee, Dwaipayan ^a,b,c   Royce, Steven G ^a,b   Alexander, Jocelyn A ^a,b   Buckley, Brian ^a   Isukapalli, Sastry S ^a,b   Bandera, Elisa V ^a,d   Zarbl, Helmut ^a,b,d   Georgopoulos, Panos G ^a,b,c,d  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c The State University of New Jersey   (United States)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLUCURONIDE; MYCOTOXIN; UNCLASSIFIED DRUG; ZEARALANONE; ZEARALENOL; ZEARALENONE; ZERANOL;

ARTICLE; BLOOD LEVEL; CHILD; CONJUGATION; DEHYDROGENATION; EXPOSURE; FECES LEVEL; FEMALE; FOOD CONTAMINATION; GLUCURONIDATION; HUMAN; NONHUMAN; PROBABILITY; RAT; SCHOOL CHILD; SIMULATION; STOMACH ABSORPTION; TOXICOKINETICS; TOXIN STRUCTURE; URINE LEVEL; ANALOGS AND DERIVATIVES; ANIMAL; BIOLOGICAL MODEL; BLOOD; BODY WEIGHT; CHEMICAL MODEL; CHEMISTRY; COHORT ANALYSIS; DRUG EFFECTS; FOOD ANALYSIS; HALF LIFE TIME; METABOLISM; MONTE CARLO METHOD; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION; UNITED STATES; URINE;

ANIMALS; BIOMARKERS; BODY WEIGHT; CHILD; COHORT STUDIES; FEMALE; FOOD ANALYSIS; HALF-LIFE; HUMANS; MODELS, BIOLOGICAL; MODELS, CHEMICAL; MONTE CARLO METHOD; NEW JERSEY; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION; TOXICOKINETICS; ZEARALENONE; ZERANOL;

EID: 84916222173     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113632     Document Type: Article

References (56)

1. Johnson R, Hanrahan C (2010) The U.S.-EU beef hormone dispute. Technical report, Congressional Research Service. Available: https://www.hsdl.org/?view&did5725844 Accessed 2010 July 19.
2. Liu S, Lin Y (2004) Transformation of MCF-10A Human Breast Epithelial Cells by Zeranol and Estradiol- 17beta. The Breast Journal 10: 514-521.
3. Kuiper-Goodman T, Scott P, Watanabe H (1987) Risk assessment of the mycotoxin zearalenone. Regulatory Toxicology & Pharmacology 7: 253-304.
4. Fara GM, Corvo GD, Bernuzzi S, Bigatello A, Pietro CD, et al. (1979) Epidemic of breast enlargement in an Italian school. The Lancet 314: 295-297.
5. Comas A (1982) Precocious sexual development in Puerto Rico. The Lancet 319: 1299-1300.
6. Schoental R (1983) Precocious sexual development in Puerto Rico and oestrogenic mycotoxins (zearalenone). The Lancet 321: 537.
7. Saenz de Rodriguez C, Bongiovanni A, Conde de Borrego L (1985) An epidemic of precocious development in Puerto Rican children. The Journal of Pediatrics 107: 393-396.
8. Massart F, Meucci V, Saggese G, Soldani G (2008) High Growth Rate of Girls with Precocious Puberty Exposed to Estrogenic Mycotoxins. The Journal of Pediatrics 152: 690-695.
9. EU Directorate-GeneralXXIV (1999) Assessment of potential risks to human health from hormone residues in bovine meat and meat products. Technical report, European Commission - Consumer policy and consumer health protection. Available: http://ec.europa.eu/food/fs/sc/scv/out21-en.pdf Accessed 2010 July 19.
10. WHO (2000) Safety evaluation of certain food additives and contaminants. Technical report, Joint FAO/ WHO Expert Committee on Food Additives (JECFA), Geneva. Available: http://www.inchem.org/documents/jecfa/jecmono/v44jec14.htm Accessed 2010 July 20.
11. Shephard GS, Burger HM, Gambacorta L, Gong YY, Krska R, et al. (2013) Multiple mycotoxin exposure determined by urinary biomarkers in rural subsistence farmers in the former Transkei, South Africa. Food and Chemical Toxicology 62: 217-225.
12. Tangni EK, Pussemier L (2007) Ergosterol and mycotoxins in grain dusts from fourteen Belgian cereal storages: A preliminary screening survey. Journal of the Science of Food and Agriculture 87: 1263-1270.
13. Wang Y, Chai T, Lu G, Quan C, Duan H, et al. (2008) Simultaneous detection of airborne Aflatoxin, Ochratoxin and Zearalenone in a poultry house by immunoaffinity clean-up and high-performance liquid chromatography. Environmental Research 107: 139-144.
14. Sewell H (1993) Growth stimulants (implants). Technical report (G2090), University of Missouri. Available: http://extension.missouri.edu/publications/DisplayPrinterFriendlyPub.aspx?P5G2090 Accessed 2011 February 16.
15. Kiessling K, Pettersson H (1978) Metabolism of Zearalenone in Rat Liver. Acta Pharmacologica et Toxicologica 43: 285-290.
16. Migdalof B, Dugger H, Heider J, Coombs R, Terry M (1983) Biotransformation of zeranol: disposition and metabolism in the female rat, rabbit, dog, monkey and man. Xenobiotica 13: 209-221.
17. Fitzpatrick D, Arbuckle L, Hassen A (1988) Zearalenone metabolism and excretion in the rat: Effect of different doses. Journal of Environmental Science and Health 23: 343-354.
18. Bories GF, Perdu-Durand EF, Sutra JF, Tulliez JE (1991) Evidence for glucuronidation and sulfation of zeranol and metabolites (taleranol and zearalanone) by rat and pig hepatic subfractions. Drug Metabolism and Disposition 19: 140-143.
19. Pfeiffer E, Hildebrand A, Damm G, Rapp A, Cramer B, et al. (2009) Aromatic hydroxylation is a major metabolic pathway of the mycoestrogen zearalenone. Molecular Nutrition & Food Research 53: 1123-1133.
20. Malekinejad H, Maas-Bakker R, Fink-Gremmels J (2005) Bioactivation of zearalenone by porcine hepatic biotransformation. Journal of Veterinary Research 36: 799-810.
21. Malekinejad H, Maas-Bakker R, Fink-Gremmels J (2006) Species differences in the hepatic biotransformation of zearalenone. The Veterinary Journal 172: 96-102.
22. Pfeiffer E, Wefers D, Hildebrand A, Fleck S, Metzler M (2013) Catechol metabolites of the mycotoxin zearalenone are poor substrates but potent inhibitors of catechol-O-methyltransferase. Mycotoxin Research 29: 177-183.
23. Hildebrand A, Pfeiffer E, Metzler M (2010) Aromatic hydroxylation and catechol formation: A novel metabolic pathway of the growth promoter zeranol. Toxicology Letters 192: 379-386.
24. Fleck S, Hildebrand A, Mller E, Pfeiffer E, Metzler M (2012) Genotoxicity and inactivation of catechol metabolites of the mycotoxin zearalenone. Mycotoxin Research 28: 267-273.
25. So MY, Tian Z, Phoon YS, Sha S, Antoniou MN, et al. (2014) Gene Expression Profile and Toxic Effects in Human Bronchial Epithelial Cells Exposed to Zearalenone. PLoS ONE 9: e96404.
26. Pfeiffer E, Hildebrand A, Mikula H, Metzler M (2010) Glucuronidation of zearalenone, zeranol and four metabolites in vitro: Formation of glucuronides by various microsomes and human UDPglucuronosyltransferase isoforms. Molecular Nutrition & Food Research 54: 1-9.
27. Baldwin R, Williams R, Terry M (1983) Zeranol: A review of the metabolism, toxicology, and analytical methods for detection of tissue residues. Regulatory Toxicology & Pharmacology 3: 9-25.
28. Miles C, Erasmuson A, Wilkins A, Towers N, Smith B, et al. (1996) Ovine Metabolism of Zearalenone to alpha-Zearalanol (Zeranol). Journal of Agricultural Food Chemistry 44: 3244-3250.
29. Kleinova M, Zollner P, Kahlbacher H, Hochsteiner W, Lindner W (2002) Metabolic profiles of the mycotoxin zearalenone and of the growth promoter zeranol in urine, liver, and muscle of heifers. Journal of Agricultural & Food Chemistry 50: 4769-4776.
30. Zollner P, Jodlbauer J, Kleinova M, Kahlbacher H, Kuhn T, Hochsteiner W, Lindner W (2002) Concentration levels of zearalenone and its metabolites in urine, mucle tissue, and liver samples of pigs fed with mycotoxin-contaminated oats. Journal of Agricultural & Food Chemistry 50: 2494-2501.
31. Shin B, Hong S, Bulitta J, Lee J, Hwang S, et al. (2009) Physiologically Based Pharmacokinetics of Zearalenone. Journal of Toxicology and Environmental Health 72: 1395-1405.
32. Videmann B, Mazallon M, Tep J, Lecoeur S (2008) Metabolism and transfer of the mycotoxin zearalenone in human intestinal Caco-2 cells. Food and Chemical Toxicology 46: 3279-3286.
33. Schaut A, DeSaeger S, Sergent T, Schneider Y, Larondelle Y, et al. (2008) Study of the gastrointestinal biotransformation of zearalanone in a caco-2 cell culture system with liquid chromatographic methods. Journal of Applied Toxicology 28: 966-973.
34. Shin B, Hong S, Bulitta J, Hwang S, Kim H, et al. (2009) Disposition, Oral Bioavailability, and Tissue Distribution of Zearalenone in Rats at Various Dose Levels. Journal of Toxicology & Environmental Health: Part A 72: 1406-1411.
35. Haritova A, Fink-Gremmels J (2010) A simulation model for the prediction of tissue:plasma partition coefficients for drug residues in natural casings. The Veterinary Journal 185: 278-284.
36. Poulin P, Theil F (2002) Prediction of Pharmacokinetics prior to In Vivo studies.II. Generic Physiologically Based Pharmacokinetic Models of Drug Disposition. Journal of Pharmaceutical Sciences 91.
37. Tukey R, Strassburg C (2000) Human udp-glucuronosyltransferases: Metabolism, expression, and disease. Annual Review of Pharmacology and Toxicology 40: 581-616.
38. Ramos A, Hernandez E, Pla-Delfina J, Merino M (1996) Intestinal absorption of zearalenone and in vitro study of non-nutritive sorbent materials. International Journal of Pharmaceutics 128: 129-137.
39. Warth B, Sulyok M, Berthiller F, Schuhmacher R, Krska R (2013) New insights into the human metabolism of the Fusarium mycotoxins deoxynivalenol and zearalenone. Toxicology Letters 220: 88-94.
40. Skopp G, Poetsch L, Mauden M, Richter B (2002) Partition coefficient, blood to plasma ratio, protein binding and short-term stability of 11-nor-delta9-carboxy tetrahydrocannabinol glucuronide. Forensic Science International 126: 17-23.
41. Barter Z, Bayliss M, Beaune P, Boobis A, Carlile D, et al. (2007) Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Current Drug Metabolism 8: 33-45.
42. Cubitt H, Houston J, Galetin A (2009) Relative importance of intestinal and hepatic glucuronidation - impact on the prediction of drug clearance. Pharmaceutical Research 26: 1073-1083.
43. Bandera EV, Chandran U, Buckley B, Lin Y, Isukapalli S, et al. (2011) Urinary mycoestrogens, body size and breast development in New Jersey girls. Sci Total Environ 409: 5221-7.
44. Georgopoulos PG, Lioy PJ (2006) From a Theoretical Framework of Human Exposure and Dose Assessment to Computational System Implementation: The Modeling ENvironment for TOtal Risk Studies (MENTOR). Journal of Toxicology and Environmental Health, Part B 9: 457-483.
45. Georgopoulos PG, Brinkerhoff CJ, Isukapalli S, Dellarco M, Landrigan PJ, et al. (2014) A Tiered Framework for Risk-Relevant Characterization and Ranking of Chemical Exposures: Applications to the National Children's Study (NCS). Risk Analysis.
46. EFSA (2011) Scientific Opinion on the risks for public health related to the presence of zearalenone in food. EFSA Journal 9.
47. Tangni EK, Waegeneers N, Van Overmeire I, Goeyens L, Pussemier L (2009) Mycotoxin analyses in some home produced eggs in Belgium reveal small contribution to the total daily intake. Science of the Total Environment 407: 4411-4418.
48. Fink-Gremmels J (2008) Mycotoxins in cattle feeds and carry-over to dairy milk: A review. Food Additives & Contaminants 25: 172-180.
49. Dixon SN, Russell KL, Heitzman RJ, Mallinson CB (1986) Radioimmunoassay of the Anabolic Agent Zeranol.5. Residues of Zeranol in the Edible Tissues, Urine, Feces and Bile of Steers Treated with Ralgro. Journal of Veterinary Pharmacology and Therapeutics 9: 353-358.
50. Coffey R, Cummins E, Ward S (2009) Exposure assessment of mycotoxins in dairy milk. Food Control 20: 239-249.
51. Beef Checkoff (2009) Beef Market At A Glance. Technical report, Cattlemen's Beef Board, National Cattlemen's Beef Association. Available: http://www.explorebeef.org/cmdocs/explorebeef/factsheet-beefmarketataglance.pdf Accessed 2014 April 25.
52. Biehl ML, Prelusky DB, Koritz GD, Hartin KE, Buck WB, et al. (1993) Biliary excretion and enterohepatic cycling of zearalenone in immature pigs. Toxicol Appl Pharmacol 121: 152-9.
53. Mallis LM, Sarkahian AB, Harris HA, Zhang MY, McConnell OJ (2003) Determination of rat oral bioavailability of soy-derived phytoestrogens using an automated on-column extraction procedure and electrospray tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 796: 71-86.
54. NHANES (2011). National health and nutrition examination survey. Available: www.cdc.gov/nchs/nhanes/Accessed 2011 September 17.
55. Fitzgerald MP, Stablein U, Brubaker L (2002) Urinary habits among asymptomatic women. Am J Obstet Gynecol 187: 1384-8.
56. Pearson MA, Lu C, Schmotzer BJ, Waller LA, Riederer AM (2009) Evaluation of physiological measures for correcting variation in urinary output: Implications for assessing environmental chemical exposure in children. J Expos Sci Environ Epidemiol 19: 336-342.